Jpmorgan Chase & CO Apellis Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 423,800 shares of APLS stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
423,800
Previous 411,549
2.98%
Holding current value
$11.5 Million
Previous $13.1 Million
29.42%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding APLS
# of Institutions
300Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$331 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$322 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$275 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$243 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.97B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...